HC Wainwright Comments on Arvinas’ Q3 Earnings (NASDAQ:ARVN)

Arvinas, Inc. (NASDAQ:ARVN) – Equities research analysts at HC Wainwright lowered their Q3 2025 earnings estimates for shares of Arvinas in a research report issued to clients and investors on Thursday, August 7th. HC Wainwright analyst A. Fein now anticipates that the company will post earnings of ($0.82) per share for the quarter, down from their prior forecast of ($0.53). HC Wainwright has a “Buy” rating and a $18.00 price target on the stock. The consensus estimate for Arvinas’ current full-year earnings is ($3.81) per share. HC Wainwright also issued estimates for Arvinas’ Q4 2025 earnings at ($0.83) EPS, FY2025 earnings at ($1.36) EPS, FY2026 earnings at ($3.06) EPS, FY2027 earnings at ($2.71) EPS, FY2028 earnings at $1.83 EPS and FY2029 earnings at $0.89 EPS.

Arvinas (NASDAQ:ARVN) last announced its quarterly earnings data on Wednesday, August 6th. The company reported ($0.84) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.87) by $0.03. Arvinas had a negative net margin of 19.47% and a negative return on equity of 12.01%. The company had revenue of $22.40 million during the quarter, compared to analyst estimates of $34.42 million. During the same period in the previous year, the business earned ($0.49) EPS. The firm’s revenue for the quarter was down 70.7% on a year-over-year basis.

Other equities research analysts also recently issued research reports about the stock. Citigroup cut their target price on shares of Arvinas from $10.00 to $9.50 and set a “neutral” rating for the company in a research report on Monday, May 5th. Leerink Partnrs downgraded shares of Arvinas from a “strong-buy” rating to a “hold” rating in a research report on Sunday, June 1st. Wells Fargo & Company cut their target price on shares of Arvinas from $19.00 to $16.00 and set an “overweight” rating for the company in a research report on Thursday. BMO Capital Markets cut their price objective on shares of Arvinas from $20.00 to $10.00 and set an “outperform” rating for the company in a research report on Monday, May 5th. Finally, BTIG Research set a $16.00 price objective on shares of Arvinas and gave the company a “buy” rating in a research report on Friday, May 2nd. Ten analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $19.76.

Arvinas Stock Up 0.8%

Shares of NASDAQ ARVN opened at $6.29 on Monday. Arvinas has a twelve month low of $5.90 and a twelve month high of $29.61. The firm has a market cap of $461.81 million, a P/E ratio of -6.23 and a beta of 2.22. The company has a 50 day moving average of $7.52 and a 200 day moving average of $9.86.

Institutional Inflows and Outflows

Several hedge funds have recently bought and sold shares of the company. Vanguard Group Inc. boosted its holdings in Arvinas by 18.4% in the 1st quarter. Vanguard Group Inc. now owns 8,362,200 shares of the company’s stock worth $58,703,000 after buying an additional 1,299,639 shares during the period. Price T Rowe Associates Inc. MD lifted its stake in Arvinas by 6.5% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 4,103,011 shares of the company’s stock worth $78,656,000 after purchasing an additional 249,295 shares in the last quarter. RTW Investments LP lifted its stake in Arvinas by 19.8% in the 4th quarter. RTW Investments LP now owns 3,334,308 shares of the company’s stock worth $63,919,000 after purchasing an additional 551,979 shares in the last quarter. T. Rowe Price Investment Management Inc. purchased a new stake in Arvinas in the 4th quarter worth $42,332,000. Finally, Alyeska Investment Group L.P. purchased a new stake in Arvinas in the 1st quarter worth $12,636,000. Institutional investors own 95.19% of the company’s stock.

Insiders Place Their Bets

In related news, CFO Andrew Saik sold 5,700 shares of the company’s stock in a transaction on Tuesday, June 24th. The shares were sold at an average price of $7.61, for a total value of $43,377.00. Following the completion of the transaction, the chief financial officer owned 164,401 shares of the company’s stock, valued at approximately $1,251,091.61. This represents a 3.35% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this link. Corporate insiders own 4.73% of the company’s stock.

Arvinas Company Profile

Arvinas, Inc, a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company engineers proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body’s own natural protein disposal system to degrade and remove disease-causing proteins.